Study wrapper · #583
Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury.
Editor's note
This is an animal study in a mouse model of acid-induced acute respiratory distress syndrome (ARDS). Researchers reported that hexarelin, a synthetic growth hormone secretagogue with described anti-inflammatory properties, improved lung compliance and reduced the number of immune cells recovered from the lungs 24 hours after injury, with fewer infiltrating neutrophils than in vehicle-treated animals. At day 14, hexarelin-treated mice showed less collagen deposition, suggesting a blunting of early fibrotic remodeling. The findings are consistent with hexarelin's proposed anti-inflammatory signaling but rest on a single acute injury model with modest group sizes. These are preclinical results; human data are needed before any clinical conclusions can be drawn, and the study does not establish that hexarelin alters clinically meaningful outcomes in lung injury.
Plain-language abstract
Researchers tested hexarelin, a lab-made peptide, in mice with a model of acute respiratory distress syndrome (severe lung injury) created by placing dilute acid into one airway. Mice received hexarelin (given into the abdomen) either before or after the acid challenge, or an inactive vehicle. Twenty-four hours later, hexarelin-treated mice had better lung mechanics and fewer inflammatory immune cells, including fewer neutrophils, in fluid washed from their lungs. When some mice were followed for 14 days, those given hexarelin had less scar-tissue (collagen) buildup in the lungs than untreated mice. The authors interpret this as hexarelin calming the early inflammatory response and limiting lung remodeling. The abstract reports no adverse events. These are preclinical findings in mice; human studies would be needed before drawing any clinical conclusions.